Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Preclinical studies show potential for single agent and combination use. Data from an in vitro IPF model has shown anti-fibrotic/anti-inflammatory activity of NXP002 alone and in combination with two approved IPF drugs. These studies suggest the addition of NXP002 may achieve the same or better activity at lower doses of the approved drugs, which may offer advantages as both have challenging side effects. Additional preclinical studies are planned as Nuformix builds out a more robust data package. Results due Q4 2021
Progress on NXP004. Research is also underway on developing new forms of an undisclosed marketed oncology drug (with sales c.$1.5bn in 2020). Results Due Q4 2021.
A patent filed in 2020 may be granted in 2022.
Licensing deal under negotiation with Oxilio. A licensing deal has been finalised with Oxilio, a private UK company, for NXP001, a novel formulation of aprepitant intended for cancer treatment.
Under the terms of the licensing agreement, Oxilio has obtained an exclusive licence to research, develop and commercialise NXP001 globally for oncology indications. Nuformix is eligible to receive an undisclosed upfront payment, development milestone payments and a royalty on net sales, capped at £2 million per annum.
Indicative value NXP002
. We believe a licensing deal or partnership for NXP002 as a Phase 1-ready asset for IPF could have a $360-450m headline value, although the upfront would be likely to be in the $10-20m range. Although, the economics of such deals are difficult to predict, the future NPV of this asset alone could be +£50m.
Fully funded
Cash to 2023. Nuformix results show net cash of £1.6m, giving a runway into late CY2022
Re-cap for newbies06
Preclinical studies show potential for single agent and combination use. Data from an in vitro IPF model has shown anti-fibrotic/anti-inflammatory activity of NXP002 alone and in combination with two approved IPF drugs. These studies suggest the addition of NXP002 may achieve the same or better activity at lower doses of the approved drugs, which may offer advantages as both have challenging side effects. Additional preclinical studies are planned as Nuformix builds out a more robust data package. Results due Q4 2021
Progress on NXP004. Research is also underway on developing new forms of an undisclosed marketed oncology drug (with sales c.$1.5bn in 2020). Results Due Q4 2021.
A patent filed in 2020 may be granted in 2022.
Licensing deal under negotiation with Oxilio. A licensing deal has been finalised with Oxilio, a private UK company, for NXP001, a novel formulation of aprepitant intended for cancer treatment.
Under the terms of the licensing agreement, Oxilio has obtained an exclusive licence to research, develop and commercialise NXP001 globally for oncology indications. Nuformix is eligible to receive an undisclosed upfront payment, development milestone payments and a royalty on net sales, capped at £2 million per annum.
Indicative value NXP002
. We believe a licensing deal or partnership for NXP002 as a Phase 1-ready asset for IPF could have a $360-450m headline value, although the upfront would be likely to be in the $10-20m range. Although, the economics of such deals are difficult to predict, the future NPV of this asset alone could be +£50m.
Fully funded
Cash to 2023. Nuformix results show net cash of £1.6m, giving a runway into late CY2022
Worth rewatching recent interview with CEO she states everything going very well both NXP002 and NXP004
https://www.youtube.com/watch?v=oqUq_8Jt8Ug
The price would probably be point 5 if I have sold my holding soup.
My negativity is aimed at the bod and their lack of respect they have for shareholders and not at the pipeline all Hope I have left here is in the product’s and the results of trials the bod have had no input in speak for themselves and then even our part time bod might manage to salvage a deal, provided they outsource a good business development manager!!
Just frustrated and can see that with the ceo soon to depart the uncertainty will be hanging over us for a while yet!!!
Everything is as it pleases them!! Couldn’t give a flying feek about shareholders!
You must be delusional if you think a deal will be sealed before Anne runs off into the sunset!!
“Anne rides with head held high” lol!!
She’s being given 10k per month other than 3/4 interviews I recall ? With the first couple reading off a script?What else has she done?
Certainly nothing that has been reflected in the share price.
So no value added at all!! More value destruction if anything
Good luck all imo we’ll need it!!
“You’re really want to get rid of a seriously good CEO who has previously developed massive drugs and an inhalation simulation for GSK because you think you know their day to day routine better than them?”
It’s going to happen sooner than later so they may as well get it over with! It’s going to knock another 10/15 percent off the share price when announced so yeah I’d prefer they just got it over with!!
Have I touched a nerve there in regards to nxp001? That’s exactly what’s happened open your eyes!! It was you that made everyone aware!!
Anne has done nothing but put us at least a year behind imo I’ll be happy to be proved wrong
“if you think that Brindley (who has previously developed a blockbuster $bn+ inhaler based drug) is sat around doing nothing then you clearly haven't a clue on what NFX is actually about.”
Sorry soup but for a company that has outsourced EVERYTHING (apparently public relations also) I do wonder exactly what if anything she does on a daily basis ? The market doesn’t think so
Come on you’ve been around long enough to see we’re all being taken for a ride. Even our old ceo has practically taken one of the products for peanuts? Why not disclose details why no broker update just ignore it and it will go away!!
It’s a joke and the problem is the uncertainty around the ceo. Feek the data it can wait they need to stabilise the ship then resume. Nfx are a laughing stock at the moment and until this issue is resolved it will stay that way.
I have a lot of respect for you for the time you put in here and how you help people more than the company does. But really it shouldn’t be a guessing game should it!
I have emailed the company and will share the response if I receive one that is.
Good luck all!!
And normally pi’s are the last to know anything so the way this has dropped off a cliff and they have removed a document which stated everything is going well from their website tells me they already know we’re feeked!
All in my opinion
You need your head checked also then if you think they’re ok!
The ceo is about to leave and we are none the wiser as to who or if they will replace her adding further uncertainty to this company!! And this is supposed to be acceptable??
They could release the best data ever known to man tomorrow and the market will still take no notice as this company is a mess from the inside out!!!
Imo we have a jumped up CEO who only cares about herself In charge(an offer she couldn’t refuse) and until she’s gone nothing is going to change. Let her go early and start to bring some organisation to this mess.
You do realise any inclination that data is bad then this is feeked!
Yes it’s very frustrating. I have watched a recent interview from Anne today and she needs to get her head checked she claims the company is in a better position now to when she joined imo it’s a feeking mess and she should be embarrassed it’s got so bad.
SORT THIS MESS OUT. It’s the least she could do for 10k a month.
They need to sort this stupid ceo issue out imo the chairman should become temporary replacement ASAP-announce to market!! Let do nothing Anne go ASAP she’s obviously not contributing anything the sooner we replace the better
They need to get their broker to write an update including explanation about CEO and new deals for nxp001 including how much revenue it will bring (if anything)
Start some basic PR even if it’s a few tweets from their twitter about current news on ipf or advances.
Anything is currently better than what you are doing-which is NOTHING!!! All in my opinion as a shareholder who has seen £132k plus turned into £65k !!!
It’s beyond a joke now!!
We are sorry, on this occasion NUFORMIX PLC could not facilitate your DDM request but looks forward to updating you at the next scheduled reporting period. DDM’s are at the sole discretion and availability of the company and that no conclusions should be made from a company declining a DDM, as defined in our terms of use policy.
Should you have any questions, please contact investorhelp@investormeetcompany.com.
Kind Regards,
The Team at Investor Meet Company
So what’s the point of them signing up to it??
Clinicians in the U.K. will now be able to prescribe the antifibrotic medicine Ofev (nintedanib) to people with non-idiopathic pulmonary fibrosis (PF) under a new decision by the National Institute for Health and Care Excellence (NICE).
That decision came following a five-year campaign led by the U.K. charity Action for Pulmonary Fibrosis — and supported by patients, families, and pulmonary disease specialists.
“This is a game changer for patients with progressive fibrosis,” Nazia Chaudhuri, PhD, a consultant respiratory physician at Manchester University National Health Service (NHS) Foundation Trust, said in a press release. “I am absolutely delighted with the NICE decision to be able to give life-changing antifibrotic therapy to all patients with progressive lung fibrosis.”
The NICE decision was welcomed by both patients and clinicians.
“This news means everything to me,” said Carol Fielding, a PF patient from Bolton, “It’s about seeing my young grandchildren reach more of their milestones and making some more memories for them. It’s about maybe living long enough that even the younger ones might remember me.”
https://pulmonaryfibrosisnews.com/2021/10/22/nice-agrees-to-allow-ofev-therapy-for-non-ipf-patients-in-uk/
Nfx Rns from March 2021
The study, performed in collaboration with the Newcastle Fibrosis Research Group, a top level multi-disciplinary research group of Newcastle University, UK, examined both the anti-fibrotic and anti-inflammatory potential of NXP002 in combination with the current SOC therapies, pirfenidone or nintedanib, using human precision cut lung slices taken from a single IPF donor.
The preliminary data from this study shows that the combination of NXP002 with SOC provided strong evidence of additional effects compared to either SOC alone on both fibrotic and inflammatory markers. In addition, the results showed evidence of similar or better activity of lower doses of SOC in combination with NXP002, compared to higher doses of SOC alone, indicating a potential for a dose-sparing effect of the combination. These data supplement the previously reported study of NXP002 in the same preclinical model where positive effects were seen when NXP002 was dosed alone and now there is strong data in combination with SOC therapy.
Dr Lee Borthwick, Senior Lecturer in Fibrosis Biology at the Newcastle Fibrosis Research Group, Newcastle University, said: "The data from this most recent study of Nuformix's drug candidate, NXP002, are very encouraging in combination with current IPF drugs and show clear attenuation of both fibrosis and inflammatory markers in combination with pirfenidone or nintedanib. This reinforces previous work done in our laboratories on this compound."
Will be us lot!!
Hate to say it but
The only explanation for the downward spiral must be someone privy to inside information selling why else?
More than £70k in the red now starting to get a little pee’ed off!!!
Come on bod pull your fingers out and do something anything must be better than nothing!!!
GLA!!